FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is a group of inventions concerning treating and preventing a disease dependent on mTOR (mammalian target of rapamycin) kinase and representing cancer or malignant growth. The group involves a pharmaceutical combination for the above application containing 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4 trifluoromethylpyridin-2-ylamine or its salt and the mTOR inhibitor everolimus; using it for preparing a drug preparation for the same application and a pharmaceutical composition containing the above combination.
EFFECT: synergetic effect of the antitumour action of 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4 trifluoromethylpyridin-2-ylamine and everolimus.
7 cl, 2 dwg
